Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Relative Bioavailability of LY03010 Compared to Listed Drug
NCT04922593 · View on ClinicalTrials.gov ↗
Study Summary
This is a randomized, multiple-dose, open-label, parallel-group study. Subjects will undergo screening evaluations to determine eligibility within 28 days prior to study drug administration. Approximately 280 eligible subjects will be randomized in a 1:1 ratio into 1 of 2 treatment groups. Subjects will be admitted to the clinical facilities the day before dosing (Day 0), and will be randomized and receive the first dosing on Day 1. Subjects will stay at site till Day 2 after PK collection. All subjects will return to the clinical sites at designated study days for dosing, PK sample collections and assigned clinical activities. All subjects randomized to LY03010 treatment group will receive the first dose of 351 mg LY03010 by IM injection on Day 1 in the deltoid muscle, followed by five (5) monthly dosing of 156 mg LY03010 in the gluteal muscle with the last dose on Day 141. All subjects randomized to SUSTENNA treatment group will receive the first dose of 234 mg SUSTENNA by IM injection on Day 1 in the deltoid muscle, and a second IM dose of 156 mg SUSTENNA on Day 8 in the deltoid muscle, followed by five (5) monthly IM dosing of 156 mg of SUSTENNA in the gluteal muscle with the last dose on Day 148. End of Study (EOS) visit for LY03010 treatment group will be on Day 169, 28 days after last dosing day; End of Study for SUSTENNA treatment group will be on Day 176, 28 days after last dosing. At EOS visit, subjects will complete the study after a series of assigned clinical assessments. A 30-day follow up call will be conducted by the clinical research staff to ensure participant's well-being.
Conditions Studied
Interventions
- DRUG LY03010; paliperidone palmitate
- DRUG INVEGA SUSTENNA
Study Locations (9)
California
- Collaborative Neuroscience Network, Inc. — Garden Grove
- Synergy San Diego — Lemon Grove
- CNS Network, LLC — Torrance
New Jersey
- Hassman Research Institute — Berlin
- Hassman Research Institute — Marlton
Texas
- InSite Clinical Research, LLC — DeSoto
- Pillar Clinical Research, LLC — Richardson
Florida
- Innovative Clinical Research, Inc. — Miami Lakes
Illinois
- Uptown Research Institute, LLC — Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 281 participants |
| Start Date | 2021-01-13 |
| Est. Completion | 2022-04-15 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04922593
The ClinicalTrials.gov registry entry for NCT04922593 describes a study currently listed as completed. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 281 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Luye Pharma Group, which has 8 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 10 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions — of which LY03010; paliperidone palmitate is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04922593 reports 9 study locations spanning 5 distinct geographic areas — top geographies include California, New Jersey, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04922593 about?
NCT04922593 is a clinical study titled "Relative Bioavailability of LY03010 Compared to Listed Drug". This is a randomized, multiple-dose, open-label, parallel-group study. Subjects will undergo screening evaluations to determine eligibility within 28 days prior to study drug administration. Approximately 280 eligible subjects will be randomized in a 1:1 ratio into 1 of 2 treatment groups. Subjects ...
What is the current status of trial NCT04922593?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 281 participants. The study started on 2021-01-13. Estimated completion is 2022-04-15.
What conditions does trial NCT04922593 study?
This clinical trial studies the following conditions: Schizophrenia, Mood Disorders, Mental Disorders, Psychotic Disorders, Physiological Effects of Drugs. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04922593?
The interventions under investigation include: LY03010; paliperidone palmitate (DRUG), INVEGA SUSTENNA (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04922593?
This trial is sponsored by Luye Pharma Group, which has 8 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04922593 being conducted?
This trial has 9 study locations across California, Florida, Illinois, New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.